These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8276316)

  • 1. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
    Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
    Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative clinical trial of regional anticoagulation for hemodialysis.
    Akizawa T; Kitaoka T; Sato M; Koshikawa S; Hirasawa Y; Kazama M; Mimura N; Ota K
    ASAIO Trans; 1988; 34(3):176-8. PubMed ID: 3058171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
    Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
    Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
    Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
    J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
    Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
    Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC)].
    Koshiyama Y; Kobori A; Ogihara M; Yokomoto Y; Ohtani K; Shimamura K; Iwaki M
    Nihon Yakurigaku Zasshi; 1987 Dec; 90(6):313-20. PubMed ID: 3443413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans.
    Abe H; Tani T; Numa K; Endo Y; Yoshioka T; Kodama M
    Artif Organs; 1992 Apr; 16(2):206-8. PubMed ID: 10078246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
    Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
    Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
    Akizawa T
    Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model.
    Minamiguchi K; Kitazato KT; Nagase H; Sasaki E; Ohwada K; Kitazato K
    Kidney Int; 2003 Apr; 63(4):1548-55. PubMed ID: 12631372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
    Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
    Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
    Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H
    Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.
    Hosokawa S; Oyamaguchi A; Yoshida O
    ASAIO J; 1992; 38(1):59-60. PubMed ID: 1554918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs.
    Choi JH; Byun SY; Nam A; Han SM; Lee KP; Song KH; Youn HY; Seo KW
    J Vet Emerg Crit Care (San Antonio); 2018 Mar; 28(2):122-129. PubMed ID: 29419934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
    Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
    Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery.
    Sato T; Tanaka K; Kondo C; Morimoto T; Yada I; Yuasa H; Kusagawa M; Deguchi K
    ASAIO Trans; 1991; 37(3):M194-5. PubMed ID: 1751106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation.
    Park JH; Her C; Min HK; Kim DK; Park SH; Jang HJ
    Int J Artif Organs; 2015 Nov; 38(11):595-9. PubMed ID: 26728787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approach to regional anticoagulation in hemodialysis using gabexate mesilate (FOY).
    Taenaka N; Shimada Y; Hirata T; Nishijima M; Yoshiya I
    Crit Care Med; 1982 Nov; 10(11):773-5. PubMed ID: 6814824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.